A clearer view of omega-3. Science, with the context left in. ↗
Home / Why trials clash

SOURCE LIBRARY · Imported evidence summary · Clinical review pending

The paradox, up close

Same drug class. Opposite verdicts.

Three trials define the confusion. Compare what actually differed and the pattern resolves: benefit needed the right molecule, a pharmacologic dose, and the right patient - all at once.

REDUCE-IT

Molecule
Dose
Who
Placebo
Result

Six variables moderate every omega-3 result: which molecule, what dose, which chemical form, who the patient is, what the comparator was, and what else the patient is taking. Trials that look contradictory almost always differ on two or more of them. The three above differ on molecule, dose, population, and placebo - which is why they can all be true at once.

The practical translation: when someone cites "a study" about omega-3, the first question is never "was it positive?" It's "which configuration did it test?" A null on 1 g/day of mixed oil in healthy adults says nothing about 4 g/day of pure EPA in statin-treated cardiac patients - and vice versa.

Key evidence

  1. [1]Bhatt DL, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia (REDUCE-IT). N Engl J Med. 2019;380:11-22.
  2. [2]Nicholls SJ, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk (STRENGTH). JAMA. 2020;324:2268-2280.
  3. [3]Manson JE, et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer (VITAL). N Engl J Med. 2019;380:23-32.
  4. [29]Griscom PV. Omega-3 Fatty Acids Are Not One Intervention: A Moderator-Matrix Review. 2026. Literature searched through July 2026. Umbrella source for this guide; claims without a numbered primary citation are synthesized there.

YOUR FIELD GUIDE

What are you curious about?